GLPG1690
GLPG1690-CL-206
Phase 2 small_molecule terminated
Quick answer
GLPG1690 for Systemic Sclerosis is a Phase 2 program (small_molecule) at Lakefront Biotherapeutics NV with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Lakefront Biotherapeutics NV
- Indication
- Systemic Sclerosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated